Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Diffuse Cutaneous Systemic Sclerosis Spiera, R. F., Hummers, L. K., Chung, L., Frech, T. M., Domsic, R. T., Hsu, V., Furst, D. E., Gordon, J. K., Mayes, M. D., Simms, R. W., Constantine, S., White, B. WILEY. 2017
View details for Web of Science ID 000411824106388